After two prior setbacks, the regulator has finally approved Ipsen’s palovarotene to treat fibrodysplasia ossificans progressiva. It’s the first treatment for the ultra-rare bone disease.
https://www.pharmalive.com/wp-content/uploads/2023/05/BiospaceFDA5-30-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-08-17 09:00:182023-08-17 09:08:58FDA approves Ipsen’s palovarotene for ultra-rare bone disease
